Table 1.
The demographics and clinical characteristics of growth and non-growth SRCs
| All patients (n = 571) |
Growth SRCs (n = 360) |
Non-growth SRCs (n = 211) | *P value | |
|---|---|---|---|---|
| Age, year | ||||
| Baseline | 51.31 ± 14.37 | 48.98 ± 14.31 | 55.28 ± 13.62 | < 0.001 |
| Final | 54.52 ± 14.27 | 52.44 ± 14.42 | 58.06 ± 13.33 | < 0.001 |
| Male, n (%) | 329 (57.6) | 196 (54.4) | 133 (63.0) | 0.045 |
| BMI, kg/m2 | ||||
| Baseline | 22.57 ± 2.86 | 22.56 ± 3.09 | 22.59 ± 2.41 | 0.924 |
| Final | 22.65 ± 2.79 | 22.62 ± 2.99 | 22.69 ± 2.42 | 0.755 |
| SBP, mmHg | ||||
| Baseline | 130.38 ± 19.58 | 130.05 ± 19.46 | 130.94 ± 19.81 | 0.602 |
| Final | 132.15 ± 17.91 | 137.26 ± 18.36 | 123.44 ± 13.16 | < 0.001 |
| DBP, mmHg | ||||
| Baseline | 79.04 ± 11.68 | 78.91 ± 11.86 | 79.25 ± 11.38 | 0.739 |
| Final | 79.71 ± 11.56 | 81.73 ± 12.25 | 76.26 ± 9.33 | < 0.001 |
| Scr, μmol/L | ||||
| Baseline | 78.57 ± 16.23 | 77.50 ± 15.92 | 80.39 ± 16.62 | 0.039 |
| Final | 90.90 ± 20.80 | 97.39 ± 20.90 | 79.82 ± 15.24 | < 0.001 |
| eGFR, mL/min/1.73 m2 | ||||
| Baseline | 96.42 ± 23.63 | 98.10 ± 23.88 | 93.54 ± 22.97 | 0.026 |
| Final | 80.72 ± 23.08 | 73.47 ± 19.62 | 93.10 ± 23.32 | < 0.001 |
| SUA, μmol/L | ||||
| Baseline | 366.25 ± 102.24 | 364.93 ± 103.53 | 368.52 ± 100.19 | 0.686 |
| Final | 360.78 ± 104.76 | 360.88 ± 105.62 | 360.61 ± 103.51 | 0.976 |
| TC, mmol/L | ||||
| Baseline | 5.06 ± 1.14 | 5.04 ± 1.13 | 5.10 ± 1.14 | 0.572 |
| Final | 5.30 ± 1.69 | 5.41 ± 1.66 | 5.13 ± 1.72 | 0.058 |
| TG, mmol/L | ||||
| Baseline | 1.19 (0.87, 1.74) | 1.19 (0.86, 1.75) | 1.18 (0.87, 1.70) | 0.958 |
| Final | 1.32 (0.94, 1.82) | 1.30 (0.92, 1.82) | 1.34 (0.94, 1.84) | 0.365 |
| Hypertension, n (%) | ||||
| Baseline | 209 (36.6) | 140 (38.9) | 69 (32.7) | 0.138 |
| Final | 198 (34.7) | 172 (47.8) | 26 (12.3) | < 0.001 |
| Renal dysfunction, n (%) | ||||
| Final | 89 (15.6) | 84 (23.3) | 5 (2.4) | < 0.001 |
| Hyperuricemia, n (%) | ||||
| Baseline | 193 (33.8) | 128 (35.6) | 65 (30.8) | 0.247 |
| Final | 204 (35.7) | 132 (36.7) | 72 (34.1) | 0.540 |
| Hypercholesterolemia, n (%) | ||||
| Baseline | 248 (43.4) | 155 (43.1) | 93 (44.1) | 0.812 |
| Final | 289 (50.6) | 194 (53.9) | 95 (45.0) | 0.041 |
| Hypertriglyceridemia, n (%) | ||||
| Baseline | 149 (26.1) | 96 (26.7) | 53 (25.1) | 0.684 |
| Final | 149 (26.1) | 113 (31.4) | 63 (29.9) | 0.702 |
| Nephrolithiasis, n (%) | ||||
| Baseline | 180 (31.5) | 113 (31.4) | 67 (31.8) | 0.928 |
| Final | 185 (32.4) | 118 (32.8) | 67 (31.8) | 0.801 |
| Hematuria, n (%) | ||||
| Baseline | 93 (16.3) | 66 (18.3) | 27 (12.8) | 0.084 |
| Final | 117 (20.5) | 89 (24.7) | 28 (13.3) | 0.001 |
| Maximum diameter, mm | ||||
| Baseline | 21.00 (14.00, 38.00) | 26.50 (16.00, 43.00) | 17.00 (12.00, 23.00) | < 0.001 |
| Final | 25.00 (16.00, 44.00) | 34.00 (23.00, 51.75) | 17.00 (12.00, 23.00) | < 0.001 |
| Yearly change in maximum diameter, mm/year | 1.00 (0.00, 2.00) | 1.67 (1.00,2.50) | – | – |
| Large cyst, n (%) | ||||
| Baseline | 316 (55.3) | 244 (67.8) | 72 (34.1) | < 0.001 |
| Final | 367 (64.3) | 295 (81.9) | 72 (34.1) | < 0.001 |
| Multiple renal cysts, n (%) | ||||
| Baseline | 170 (29.8) | 117 (32.5) | 53 (25.1) | 0.063 |
| Final | 210 (36.8) | 157 (43.6) | 53 (25.1) | < 0.001 |
BMI body mass index; SBP systolic blood pressure; DBP diastolic blood pressure; Scr serum creatinine; eGFR estimated glomerular filtration rate; SUA serum uric acid; TC total cholesterol; TG triglyceride
*Compared growth SRCs with non-growth SRCs